

Haematologica
HAEMATOL/2019/228684
Version 1

Carfilzomib combination treatment as first line therapy in multiple
myeloma: quo vadis from the Carthadex (KTd)-trial update?

Monika Engelhardt, Kwee L Yong, Sara Bringhen, and Ralph Wäsch

Disclosures: SB has received honoraria from Bristol-Myers Squibb, Celgene, Amgen and Janssen; has served on the advisory boards for Amgen, Karyopharm, Janssen and Celgene; and has received consultancy fees from Takeda and Janssen. ME has received educational and trial support from Amgen, Celgene, Takeda, BMS, Janssen, Novartis, Karyopharm, and has received honoraria and consultancy fees from BMS, Celgene, Amgen, Takeda, Novartis and Janssen. KLY: Research funding from Amgen RW: Consulting: Sanofi, Pfizer, Gilead, Novartis, Amgen, Takeda; Research: Sanofi; Travel: Gilead, Jazz, Celgene, Amgen

Contributions: All authors equally contributed